Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Sarcura, an Austria-based personalised cell therapy manufacturing process developer affiliated to Institute of Science and Technology (IST) Austria, has closed a €2.5m ($3m) seed round featuring IST Cube, the institute’s seed fund. The deal was rounded off by Nina Capital and Axilium Capital, and also included a grant through economic development bank Austria Wirtschaftsservice. Founded in 2019, Sarcura aims to enable industrial-scale production of cell therapies using silicon chip-based technologies. The cash will go to progressing its first product.
